MBX Biosciences Presents Preliminary Phase 1 Data for Obesity Candidate MBX 4291

Bitget2026/11/09 21:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MBX Biosciences reported 7% mean weight loss at eight weeks in MBX 4291's first eight-person multiple-dose cohort, including two placebo recipients.
The ongoing, blinded Phase 1 trial recorded no serious adverse events; one participant experienced mild diarrhea, with no nausea or vomiting.
Twelve-week multiple-dose data for the obesity candidate are expected in the fourth quarter of 2026.
Canvuparatide, an investigational once-weekly treatment for hypoparathyroidism, is in an ongoing Phase 3 trial targeting 160 patients.
Cash of $481.6 million is expected to fund operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MBX Biosciences Presents Preliminary Phase 1 Data for Obesity Candidate MBX 4291

You may also like

Crypto prices